Overview: Fibrinogen Clotting TestIntroduction: The Fibrinogen Clotting Test measures fibrinogen activity to diagnose clotting disorders, causing bleeding or thrombosis. Aligned with 2023 ASH guidelines, it uses an immunoassay for high specificity, aiding in coagulation screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected clotting disorders.
Other Names: Fibrinogen Assay, Clotting Factor Test.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.
Historical Milestone: Fibrinogen testing began in the 1950s with coagulation research. Functional assays emerged in the 1970s, and by the 2000s, standardized immunoassays improved accuracy.
Purpose: Diagnoses clotting disorders, guides therapy, and monitors fibrinogen activity in patients with bleeding or thrombosis.
Test Parameters: 1. Fibrinogen Clotting Activity
Pretest Condition: No fasting required. Collect plasma at any time. Report symptoms like bleeding or thrombosis, and list medications like anticoagulants.
Specimen: 2-4 mL plasma (NaCit). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document bleeding, thrombosis, or history of clotting disorders (e.g., hypofibrinogenemia). Include current medications, especially anticoagulants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for therapy.
Procedural Considerations: Uses an immunoassay to measure fibrinogen clotting activity. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Anticoagulants or improper storage can affect results. Hemolysis may reduce accuracy.
Clinical Significance: Abnormal fibrinogen activity suggests clotting disorders, prompting therapy. Normal activity may require further testing.
Specialist Consultation: Consult a hematologist for result interpretation.
Additional Supporting Tests: FDP, PT/INR, or thrombin time to confirm clotting disorders.
Test Limitations: Results may be affected by medications. Clinical correlation is required.
References: ASH Coagulation Guidelines, 2023; Journal of Thrombosis and Haemostasis, Weitz JI, 2022.
